We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$1.65M
Cap. Flow
+$718
Cap. Flow %
0%
Top 10 Hldgs %
60.41%
Holding
141
New
23
Increased
22
Reduced
12
Closed
32

Top Buys

Rank Stock Value
1
INMB icon
INmune Bio
INMB
+$5.31M
2
STAA icon
STAAR Surgical
STAA
+$5.12M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$2.44M
4
NVNO
enVVeno Medical
NVNO
+$1.94M
5
CVX icon
Chevron
CVX
+$1.6M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.85M
2
U icon
Unity
U
+$3.33M
3
SKIN icon
SkinHealth Systems
SKIN
+$2.9M
4
FFIV icon
F5
FFIV
+$2.71M
5
NVAX icon
Novavax
NVAX
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 78.61%
2 Financials 5.86%
3 Technology 3.93%
4 Communication Services 3.41%
5 Consumer Discretionary 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYT
76
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$263K 0.14%
15,000
+14,910
+16,567% +$279K
U icon
77
Unity
U
$15.5B
$253K 0.13%
2,000
-28,100
-93% -$3.33M
ORIO
78
Orion Digital Corp
ORIO
$15.6M
$238K 0.12%
18,333
+2,500
+16% +$41.5K
SYRS
79
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$235K 0.12%
5,250
– –
YCBD icon
80
cbdMD
YCBD
$6.19M
$213K 0.11%
+285
New +$239K
SDPI
81
DELISTED
Superior Drilling Products Inc.
SDPI
$206K 0.11%
117,500
-5,000
-4% -$4.01K
CLRB icon
82
Cellectar Biosciences
CLRB
$20.1M
$201K 0.1%
725
– –
TIL icon
83
Instil Bio
TIL
$49.2M
$179K 0.09%
500
– –
RNAZ icon
84
TransCode Therapeutics
RNAZ
$4.5M
– –
0
– –
EGLX
85
DELISTED
Enthusiast Gaming Holdings Inc. Common Stock
EGLX
$145K 0.08%
40,000
– –
ACIU icon
86
AC Immune
ACIU
$233M
$144K 0.07%
+21,500
New +$154K
QDEL icon
87
QuidelOrtho
QDEL
$1.19B
$141K 0.07%
1,000
-5,100
-84% -$686K
CLGN icon
88
CollPlant Biotechnologies
CLGN
$5.86M
$127K 0.07%
7,500
– –
ALXO icon
89
ALX Oncology
ALXO
$258M
$111K 0.06%
+1,500
New +$100K
TCON
90
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$110K 0.06%
1,425
– –
CHRS icon
91
Coherus Oncology
CHRS
$224M
$104K 0.05%
6,500
– –
GTH
92
DELISTED
Genetron Holdings Limited ADS
GTH
$104K 0.05%
2,500
– –
AVDL
93
DELISTED
Avadel Pharmaceuticals
AVDL
$103K 0.05%
10,500
– –
YALA
94
Yalla Group
YALA
$815M
$102K 0.05%
13,500
– –
BLPH
95
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$102K 0.05%
25,000
– –
ARAV
96
DELISTED
Aravive, Inc. Common Stock
ARAV
$87K 0.05%
23,500
– –
KPTI icon
97
Karyopharm Therapeutics
KPTI
$43.3M
$81K 0.04%
933
– –
BLRX
98
BioLineRX
BLRX
$11.8M
$76K 0.04%
688
– –
ZVO
99
DELISTED
Zovio Inc. Common Stock
ZVO
$72K 0.04%
30,000
– –
CLF icon
100
Cleveland-Cliffs
CLF
$7.22B
$63K 0.03%
3,200
+200
+7% +$4.56K
2 3
4
5 6

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, ACT Capital Management held 141 positions worth $193M, down 0.85% from $195M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

ACT Capital Management's Q3 2021 filing shows 23 new, 22 increased, 12 reduced and 32 closed positions. Its largest new stake was INmune Bio: 275,000 shares worth $5.34M. The largest sale was Filana Therapeutics, an estimated $3.85M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials and Technology.

  • ACT Capital Management's largest Q3 2021 buy was INmune Bio: 275,000 shares worth $5.34M.
  • ACT Capital Management added most to STAAR Surgical in Q3 2021, an estimated $5.12M increase.
  • ACT Capital Management's biggest Q3 2021 reduction was Unity, cutting an estimated $3.33M.
  • ACT Capital Management fully exited Filana Therapeutics in Q3 2021, selling an estimated $3.85M.
  • ACT Capital Management's ten largest holdings make up 60% of its $193M portfolio in Q3 2021.
  • ACT Capital Management opened 23 new positions and closed 32 in Q3 2021.
  • ACT Capital Management's portfolio value fell 0.85% quarter-over-quarter to $193M.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.